CrossrefInfokarte
Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer
Clinical Journal of Oncology Nursing · 2020-06-01 · 24 (3) · 277-283
DOI: 10.1188/20.cjon.277-283 ↗Abstract
Kein Abstract verfügbar.
EUVIMED